MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

Sandra Van Schaeybroeck, Christian Rolfo, Elena Elez, Stephen Kelly, Jennifer Houlden, Linda Collins, Sharon Love, Thierry Andre, Mark lawler, Federica Di Nicolantonio, Margaret Grayson, Vlad Popovici, alberto Bardelli, Pierre Laurent=puig, Manuel Salto-Tellez, Tim Maughan, Josep Tabernero, Marc Peeters, Richard Wilson, Mark Middleton

Research output: Contribution to journalMeeting abstract

Abstract

Background: RAS is mutated (RASMT) in ~55% of mCRC, and phase III studies have shown that patients harbouring RAS mutations do not benefit from anti-EGFR MoAbs. In addition, ~50% of RAS Wild Type (RASWT) will not benefit from the addition of an EGFR MoAb to standard chemotherapy. Hence, novel treatment strategies are urgently needed for RASMT and > 50% of RASWT mCRC patients. c-MET is overexpressed in ~50-60%, amplified in ~2-3% and mutated in ~3-5% of mCRC. Recent preclinical studies have shown that c-MET is an important mediator of resistance to MEK inhibitors (i) in RASMT mCRC, and that combined MEKi/METi resulted in synergistic reduction in tumour growth in RASMT xenograft models (1). A number of recent studies have highlighted the role of c-MET in mediating primary/secondary resistance to anti-EGFR MoAbs in mCRC, suggesting that patient with RASWT tumours with aberrant c-MET (RASWT/c-MET+) may benefit from anti-c-MET targeted therapies (2). These preclinical data supported the further clinical evaluation of combined MEKi/METi treatment in RASMT and RASWT CRC patients with aberrant c-MET signalling (overexpression, amplification or mutation; RASWT/c-MET+). Methods: MErCuRIC1 is a phase I combination study of METi crizotinib with MEKi PD-0325901. The dose escalation phase, utilizing a rolling six design, recruits 12-24 patients with advanced solid tumours and aims to assess safety/toxicity of combination, recommended phase II (RPII) dose, pharmacokinetics (PK) and pharmacodynamics (PD) (pERK1/2 in PBMC and tumour; soluble c-MET). In the dose expansion phase an additional 30-42 RASMT and RASWT/c-MET mCRC patients with biopsiable disease will be treated at the RPII dose to further evaluate safety, PK, PD and treatment response. In the dose expansion phase additional biopsy and blood samples will be obtained to define mechanisms of response/resistance to crizotinib/PD-0325901 therapy. Enrolment into the dose escalation phase began in December 2014 with cohort 1 still ongoing. EudraCT registry number: 2014-000463-40. (1) Van Schaeybroeck S et al. Cell Reports 2014;7(6):1940-55; (2) Bardelli A et al. Cancer Discov 2013;3(6):658-73. Clinical trial information: 2014-000463-40.
Original languageEnglish
JournalJournal of Clinical Oncology
Volume33
Issue number(suppl; abstr TPS3632)
Publication statusPublished - 2015
Event2015 ASCO Annual Meeting - McCormick Place, Chicago, United States
Duration: 29 May 201502 Jun 2015

Fingerprint Dive into the research topics of 'MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.'. Together they form a unique fingerprint.

  • Cite this

    Van Schaeybroeck, S., Rolfo, C., Elez, E., Kelly, S., Houlden, J., Collins, L., Love, S., Andre, T., lawler, M., Di Nicolantonio, F., Grayson, M., Popovici, V., Bardelli, A., Laurent=puig, P., Salto-Tellez, M., Maughan, T., Tabernero, J., Peeters, M., Wilson, R., & Middleton, M. (2015). MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. Journal of Clinical Oncology, 33((suppl; abstr TPS3632)). http://meetinglibrary.asco.org/content/151724-156